Elizabeth Plimack, MD, MS, Talks Risk Categories in KEYNOTE-426 Trial on Advanced RCC
Elizabeth Plimack, MD, MS, discussed the analysis of risk categories for patients included in the KEYNOTYE-426 trial investigating axitinib and pembrolizumab over sunitinib for patients with advanced renal cell carcinoma.
Systemic Therapy for Advanced Bladder Cancer Evolves
Dr. Elizabeth Plimack discusses her 2018 AACR meeting presentation on recent advances in systemic therapy for bladder cancer.
2 Clarke Drive Cranbury, NJ 08512